Summary of Key Points
The export of Chinese innovative drugs is entering an acceleration phase: In the first half of this year, the amount of licensing transactions reached 80% of the 2025 target, covering multiple fields and countries. Pharmaceutical companies are more confident and have diversified strategies; however, they still face challenges such as a lack of original innovation, a shortage of talent, and an incomplete industrial infrastructure. Experts suggest optimizing overseas business development (BD) strategies by matching product characteristics with appropriate cooperation models, seizing the right timing for transactions, and focusing on future hot sectors (such as ADCs).
I. Outstanding Achievements in Overseas Expansion: Record-Scale Transactions and Increased Global Recognition
From January to June this year, China granted 81 licenses for its innovative drugs, totaling approximately $110 billion—80% of the annual target for 2025, marking the highest half-year figure on record. The transactions covered 10 therapeutic areas, including oncology and metabolism, with buyers coming from over 20 countries (mainly the United States and Europe). This indicates that:
- The technical strength of Chinese innovative drugs has been recognized by international markets (multinational pharmaceutical companies are willing to pay high prices for these pipelines);
- Overseas expansion is no longer just an individual company's endeavor but a trend across the entire industry, with an increasingly broad range of fields and regions involved.
II. Three Major Challenges in Overseas Expansion
Despite the positive results, experts have identified several key difficulties:
1. Lack of Original Innovation and Weak Basic Research: Many drugs are not entirely new inventions but rather improvements based on existing targets, lacking true global-first innovations;
2. Insufficient Talent and Translation Capability: There is a shortage of professionals skilled in designing clinical trials for overseas markets. Overseas regulatory agencies (such as the FDA) have strict requirements, and non-compliant designs can prevent drug approval. Additionally, the conversion rate of innovative targets from laboratory to clinical application is low, increasing research and development risks;
3. Inadequate Industrial Support: For example, in the field of nuclear medicine, there is a lack of contract research organizations (CROs) capable of conducting overseas trials, as well as production facilities that meet international standards. The drug review system and regulations need to be better aligned with international practices to facilitate the adoption of cutting-edge technologies.
III. BD Strategies: Choosing the Right Cooperation Model Based on Product Characteristics
Business development (BD) involves selling drugs overseas or collaborating with foreign companies. Experts recommend selecting the right model based on product characteristics:
- For mass-market products (such as medications for Helicobacter pylori): License directly to multinational corporations (MNCs), which have established global distribution networks, saving time and reducing risks;
- For niche products (such as drugs for orthopedic infections): Consider joint development or establishing new companies, as these drugs require significant investment in both research and marketing;
- For early-stage projects: Wait until the financing environment is favorable before selling—this can lead to higher prices due to more substantial data.
IV. Timing of BD Transactions: Seizing the Right Moment for Better Prices
The timing of transactions is crucial and is influenced by three factors: clinical data, regulatory policies, and the financing environment:
- Clinical Data: Conduct low-cost investigator-initiated trials (IITs) to validate efficacy before entering into licensing discussions; more substantial data will attract higher offers from buyers;
- Regulatory Policies: For instance, if the FDA tightens requirements for single-arm clinical trials, the value of related drugs may decrease, so it's important to avoid such periods;
- Financing Environment: If the market is financing-friendly, early-stage projects can be held onto until their valuation increases, allowing for better deals.
V. Future Opportunities: ADC Pipelines as a Hotspot, with Experienced Companies at an Advantage
Experts predict many opportunities in overseas BD over the next 2-3 years:
- ADC Pipelines: Multinational companies are seeking projects for antibody-drug conjugates (ADCs), a new type of cancer therapy. Local companies should prepare in advance;
- Experienced Companies: Those with past experience in large-scale overseas licensing agreements will be more attractive to investors;
- Solid-Data Projects: Projects with robust clinical data can benefit from long-term collaborations with multinational corporations, allowing for the gradual maximization of platform value.
In summary, while Chinese innovative drugs are making significant progress in their international market presence, they still need to address shortcomings in basic research, talent, and industrial infrastructure. By adopting the right strategies and timing their moves, they can become a true global force in innovation. The next few years will be a critical battleground for this industry.